Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?

Submitted: 12 October 2014
Accepted: 22 December 2014
Published: 31 March 2015
Abstract Views: 2339
PDF: 2190
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Rossini, M., Viapiana, O., Orsolini, G., Fracassi, E., Idolazzi, L., Gatti, D., … Govoni, M. (2015). Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?. Reumatismo, 66(4), 285–303. https://doi.org/10.4081/reumatismo.2014.799

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.